Melaiu, O., Mina, M., Chierici, M., Boldrini, R., Jurman, G., Romania, P., et al. (2017) PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research.

has been cited by the following article:

• TITLE: N-Myc Inhibition: Advances in Neuroblastoma Treatment

  AUTHORS: Md Kamrul Hasan

  KEYWORDS: Neuroblastoma, N-Myc, PI3K/mTOR, PARP1, PD-L1, HAUSP

  JOURNAL NAME: CellBio, Vol.6 No.3, September 30, 2017

  ABSTRACT: Neuroblastoma (NBL) is one of the most common solid tumors and around 15% of cancer mortality in children. Amplification of the N-Myc proto-oncogene is strongly correlated with advanced disease and poor clinical outcome in NBL. Recent studies described that ubiquitin-specific protease 7 (USP7; also known as HAUSP) interacts with N-Myc, induces deubiquitination and subsequent stabilization of N-Myc that in-turn potentiates N-Myc function, and treatment with the HAUSP inhibitor (P22077) blocked such effects.